A Phase-3, Randomized, Placebo-Controlled, 12-Week, Double-Blind Study to Assess Efficacy and Safety of Fezolinetant, a Neurokinin-3 Receptor Antagonist, in Women with Moderate-to-Severe Vasomotor Symptoms Associated with Menopause
Titel:
A Phase-3, Randomized, Placebo-Controlled, 12-Week, Double-Blind Study to Assess Efficacy and Safety of Fezolinetant, a Neurokinin-3 Receptor Antagonist, in Women with Moderate-to-Severe Vasomotor Symptoms Associated with Menopause
Auteur:
Shapiro, Marla Johnson, Kimball Nappi, Rossella E. Neal-Perry, Genevieve Stute, Petra Thurston, Rebecca C. Wolfman, Wendy English, Marci Franklin, Catherine Lee, Misun Santoro, Nanette